sleeve gastrectomy / Bariatric Sleeve Gastrectomy · Observational Study

Impact of Asprosin and Neuregulin 4 on Metabolic Parameters, Anthropometric Indices and Body Composition After Laparoscopic Sleeve Gastrectomy

ClinicalTrials.gov · September 8, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a completed observational registry record of a study measuring serum asprosin and neuregulin 4 alongside metabolic markers and body composition after laparoscopic sleeve gastrectomy. No results are posted in this registry entry. The study aims to characterise whether changes in these adipose-derived hormones associate with metabolic improvement independently of weight loss, but outcome data are not available for evaluation.

What was studied

Observational. Bariatric Sleeve Gastrectomy; age from 18 Years; to 60 Years; accepts healthy volunteers. Intervention: Surgical; Reference; Evaluable. n = 160. 1 site: Egypt.

Key findings

Safety

Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

This is a completed observational registry record with no results posted; it describes planned measurement of novel biomarkers after bariatric surgery but carries no outcome data to evaluate.

Study design

As stated by the source record.

MethodsCohort model. Prospective time perspective. Primary outcome measures: log-transformed fasting serum asprosin and NRG4 (assessed at 6 months); HOMA-IR (assessed at 6 months)

DesignObservational

PopulationBariatric Sleeve Gastrectomy; age from 18 Years; to 60 Years; accepts healthy volunteers

Sample size160

InterventionSurgical; Reference; Evaluable

Setting1 site: Egypt

Reported figures

Quoted from the source exactly as published.

Sample size160

Primary outcome measure 1log-transformed fasting serum asprosin

Primary outcome measure 1 timepoint6 months

Primary outcome measure 2log-transformed fasting serum NRG4

Primary outcome measure 2 timepoint6 months

Primary outcome measure 3HOMA-IR

Primary outcome measure 3 timepoint6 months

Follow-up duration12 months

Caveats

No results posted in this registry record; outcome data, effect sizes, and statistical significance cannot be evaluated.
Observational design without control or comparator group; cannot distinguish weight-loss-dependent effects from direct surgical effects.
Primary outcomes measured at 6 months only in registry; follow-up stated as 12 months but measurement schedule incompletely specified.
Setting, country detail, and detailed eligibility criteria not provided in registry summary.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

limited

Observational design without control arm; cannot isolate surgery effect from weight loss.

Directness

moderate

Directly measures stated biomarkers and metabolic indices; surrogate endpoints rather than clinical outcomes.

Consistency

insufficient

Registry record only; no results posted to assess consistency with prior work.

Risk of bias

insufficient

No results or methods detail; observational design vulnerable to confounding.

Sample adequacy

moderate

160 enrolled participants; adequate for exploratory biomarker work but not stated if powered.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT07806448). This is a study registration, not published results. Lead sponsor: General Committee of Teaching Hospitals and Institutes, Egypt. Recruitment status: COMPLETED. Study type: OBSERVATIONAL. Enrollment: 160 participants (ACTUAL). Conditions: Bariatric Sleeve Gastrectomy. Interventions: PROCEDURE: sleeve gastrectomy. Primary outcome measures: log-transformed fasting serum asprosin and NRG4 , 6 months; HOMA-IR , 6 months. Brief summary: Asprosin and neuregulin 4 (NRG4) sit on opposing arms of adipose endocrine physiology. Asprosin is a fasting-induced, white adipose-derived glucogenic and orexigenic hormone that rises with adiposity and insulin resistance. NRG4 is a brown and beige adipose-derived, anti-lipogenic and hepatoprotective factor that falls with adiposity. Both have been examined separately after metabolic and bariatric surgery, but never in the same cohort, and existing surgical data cannot separate a weight-loss-dependent effect from an effect of the operation itself. Objectives: To quantify the change in fasting serum asprosin and NRG4 over twelve months after laparoscopic sleeve gastrectomy (LSG); to determine whether those changes are associated with metabolic improvement independently of weight loss; and to characterise their relationship with anthropometric indices and body composition.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

sleeve gastrectomyGeneral Committee of Teaching Hospitals and Institutes, EgyptBariatric Sleeve GastrectomyNCT07806448